Moffett Brady S, Valdes Santiago O, Kim Jeffrey J
Department of Pharmacy, Texas Children's Hospital, 6621 Fannin St, MC 2-2510, Houston, TX, 77030, USA,
Pediatr Cardiol. 2013;34(8):1762-6. doi: 10.1007/s00246-013-0710-8. Epub 2013 May 3.
Laboratory monitoring of amiodarone therapy is recommended due to the high incidence of adverse events associated with the drug. The use of appropriate monitoring is unknown at pediatric hospitals. The Pediatric Health Information System database was queried during a 5-year period for all patients who received amiodarone while hospitalized. Use of thyroid function testing, hepatic function testing, electrocardiogram, pulmonary function testing, and chest X-ray for patients was identified. Incidence of individual monitoring tests and complete monitoring profile was identified and compared across patient demographic and clinical factors and pediatric hospital. A total of 1,703 patients met the study criteria, and the incidence of complete amiodarone monitoring for all patients was 7.6 %. The least common monitoring test performed was triiodothyronine at 19.4 %, and the most common was electrocardiogram at 89.7 %. Critically ill patients and neonates were more likely to have amiodarone monitoring. Considerable variation in monitoring practices between pediatric hospitals was identified. Monitoring of amiodarone therapy in patients admitted to pediatric hospitals is low. Future efforts to standardize care are warranted.
由于胺碘酮治疗相关不良事件的发生率较高,因此建议对胺碘酮治疗进行实验室监测。在儿科医院,适当监测的使用情况尚不清楚。在5年期间,对儿科健康信息系统数据库中所有住院期间接受胺碘酮治疗的患者进行了查询。确定了患者使用甲状腺功能测试、肝功能测试、心电图、肺功能测试和胸部X光检查的情况。确定并比较了个体监测测试的发生率和完整监测情况,以及患者的人口统计学和临床因素及儿科医院之间的差异。共有1703名患者符合研究标准,所有患者的胺碘酮完整监测发生率为7.6%。执行最少的监测测试是三碘甲状腺原氨酸,为19.4%,最常见的是心电图,为89.7%。重症患者和新生儿更有可能接受胺碘酮监测。已确定儿科医院之间的监测做法存在相当大的差异。儿科医院住院患者的胺碘酮治疗监测率较低。未来有必要努力规范治疗。